tiprankstipranks
Voyageur Pharmaceuticals (VYYRF)
OTHER OTC:VYYRF

Voyageur Pharmaceuticals (VYYRF) Stock Price & Analysis

2 Followers

VYYRF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.03 - $0.10
Previous Close$0.08
Volume150.00
Average Volume (3M)7.60K
Market Cap
$5.77M
Enterprise Value$5.79M
Total Cash (Recent Filing)C$1.88K
Total Debt (Recent Filing)C$25.52K
Price to Earnings (P/E)-9.8
Beta29.28
Apr 26, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding132,702,406
10 Day Avg. Volume1,515
30 Day Avg. Volume7,599
Standard Deviation0.48
R-Squared0.00214
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)2.50
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)2.70
P/FCF Ratio2.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

20.05%0.00%0.00%79.95%
20.05% Insiders
0.00% Other Institutional Investors
79.95% Public Companies and
Individual Investors

VYYRF FAQ

What was Voyageur Pharmaceuticals’s price range in the past 12 months?
Voyageur Pharmaceuticals lowest stock price was $0.03 and its highest was $0.10 in the past 12 months.
    What is Voyageur Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Voyageur Pharmaceuticals’s upcoming earnings report date?
    Voyageur Pharmaceuticals’s upcoming earnings report date is Apr 26, 2024 which is 6 days ago.
      How were Voyageur Pharmaceuticals’s earnings last quarter?
      Currently, no data Available
      Is Voyageur Pharmaceuticals overvalued?
      According to Wall Street analysts Voyageur Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Voyageur Pharmaceuticals pay dividends?
        Voyageur Pharmaceuticals does not currently pay dividends.
        What is Voyageur Pharmaceuticals’s EPS estimate?
        Voyageur Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Voyageur Pharmaceuticals have?
        Voyageur Pharmaceuticals has 132,702,410 shares outstanding.
          What happened to Voyageur Pharmaceuticals’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Voyageur Pharmaceuticals?
          Currently, no hedge funds are holding shares in VYYRF
          ---

          Voyageur Pharmaceuticals Stock Smart Score

          N/A
          Not Ranked
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Technicals

          SMA
          Positive
          20 days / 200 days
          Momentum
          -20.00%
          12-Months-Change

          Fundamentals

          Return on Equity
          -97.22%
          Trailing 12-Months
          Asset Growth
          3.25%
          Trailing 12-Months

          Company Description

          Voyageur Pharmaceuticals

          Voyageur Pharmaceuticals Ltd. engages in mineral exploration. It focuses on VM Frances Creek NI-43-101 July 2018, VM Lithium 2017, Frances Creek, Jubilee Mountain, Pedley Mountain and Jubilee Zinc base metal discovery. The company was founded on July 23, 2008 and is headquartered in Calgary, Canada.
          ---
          Similar Stocks
          Company
          Price & Change
          Follow
          Voyager Therapeutics
          Novavax
          Ocugen
          VBI Vaccines
          Popular Stocks
          ---
          What's Included in PREMIUM?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis